• Atea Pharmaceuticals initiated a first-in-human Phase 1 trial of AT-587 for hepatitis E virus, a disease with no approved therapies.
• Randomized, double-blind, placebo-controlled study in healthy volunteers to assess safety, tolerability, pharmacokinetics, food effect, SAD, MAD.
• Preclinical data cited 30- to 150-fold higher in vitro potency versus sofosbuvir and ribavirin; in vivo activity shown in HEV genotype 3 model.
• Program positions AT-587 as a potential first-in-class oral HEV treatment, targeting immunocompromised patients at risk of chronic infection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.